MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-07-2025
Fulgent Genetics Operating Income 2011-2026 | FLGT
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Fulgent Genetics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -73.9 M | -196 M | 179 M | 676 M | 290 M | -428 K | -5.07 M | -3.48 M | 918 K | -5.01 M | -990 K | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 676 M | -196 M | 78.3 M |
Quarterly Operating Income Fulgent Genetics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -15.4 M | -19.7 M | -19.8 M | - | -17.1 M | -18.9 M | -21.8 M | - | 214 K | -19.8 M | -24.8 M | - | 352 K | 12.8 M | 202 M | 151 M | 159 M | 98.9 M | 267 M | 226 M | 63.5 M | 2.64 M | -1.91 M | -409 K | 1.51 M | 295 K | -1.82 M | -1.03 M | -846 K | -1 M | -2.19 M | -2.07 M | -1.48 M | -150 K | 219 K | 1.26 M | -695 K | 970 K | -615 K | -7.34 M | 1.18 M | 747 K | 405 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 267 M | -24.8 M | 25.3 M |
Operating Income of other stocks in the Diagnostics research industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
1.35 B | $ 117.5 | 2.1 % | $ 35.7 B |  USA |
 |
Check-Cap Ltd.
CHEK
|
-25.9 M | - | - | $ 9.42 M |  Israel |
 |
Aspira Women's Health
AWH
|
-7.91 M | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
-32 M | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
-23.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | USA |
 |
CareDx, Inc
CDNA
|
-30.8 M | $ 16.83 | 4.86 % | $ 897 M | USA |
 |
Exact Sciences Corporation
EXAS
|
-206 M | - | - | $ 19.8 B | USA |
|
Akumin
AKU
|
-28.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Enzo Biochem
ENZ
|
-12.4 M | - | -8.98 % | $ 14.8 K | USA |
 |
Co-Diagnostics
CODX
|
-50.2 M | $ 1.45 | 5.84 % | $ 1.93 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-14 M | - | -61.36 % | $ 2.46 M | USA |
 |
Castle Biosciences
CSTL
|
8.67 M | $ 23.53 | 1.73 % | $ 654 M | USA |
 |
Global Cord Blood Corporation
CO
|
609 M | - | - | $ 399 M |  China |
 |
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | China |
 |
Charles River Laboratories International
CRL
|
25.2 M | $ 178.34 | 1.53 % | $ 8.84 B | USA |
 |
Interpace Biosciences
IDXG
|
4.08 M | $ 2.2 | -4.35 % | $ 9.73 M | USA |
 |
Danaher Corporation
DHR
|
4.69 B | $ 195.87 | 3.3 % | $ 140 B | USA |
 |
Heska Corporation
HSKA
|
-20.3 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-20.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
-833 M | $ 126.96 | 4.99 % | $ 20.2 B | USA |
 |
Guardant Health
GH
|
-437 M | $ 82.21 | 4.59 % | $ 10.3 B | USA |
 |
QIAGEN N.V.
QGEN
|
466 M | - | - | $ 10.6 B |  Niderland |
 |
Anixa Biosciences
ANIX
|
-11.7 M | $ 2.85 | 5.95 % | $ 92.5 K | USA |
 |
Medpace Holdings
MEDP
|
535 M | $ 501.23 | 1.56 % | $ 14.5 B | USA |
 |
Biomerica
BMRA
|
-5.14 M | $ 2.08 | -2.8 % | $ 4.78 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
553 M | $ 28.55 | 0.87 % | $ 20 B | Niderland |
 |
ICON Public Limited Company
ICLR
|
1.1 B | $ 110.37 | 3.33 % | $ 9.1 B |  Irlanda |
 |
Laboratory Corporation of America Holdings
LH
|
1.38 B | $ 264.18 | 1.25 % | $ 22 B | USA |
 |
Celcuity
CELC
|
-172 M | $ 120.4 | 2.78 % | $ 5.63 B | USA |
 |
Myriad Genetics
MYGN
|
-387 M | $ 4.59 | 5.52 % | $ 425 M | USA |
 |
NeoGenomics
NEO
|
-116 M | $ 8.0 | 4.03 % | $ 1.02 B | USA |
 |
Neogen Corporation
NEOG
|
-1.06 B | $ 9.14 | -2.97 % | $ 1.98 B | USA |
 |
Lantheus Holdings
LNTH
|
311 M | $ 81.67 | 1.34 % | $ 5.51 B | USA |
 |
Motus GI Holdings
MOTS
|
-11.9 M | - | -34.28 % | $ 263 K | Israel |
 |
Natera
NTRA
|
-541 M | $ 201.9 | 4.6 % | $ 19.9 B | USA |
 |
Invitae Corporation
NVTA
|
-94.9 M | - | - | $ 21.2 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.56 B | $ 192.91 | 0.73 % | $ 21.4 B | USA |
 |
ENDRA Life Sciences
NDRA
|
-5.76 M | $ 5.19 | 5.06 % | $ 4.08 M | USA |
 |
National Research Corporation
NRC
|
22.6 M | $ 16.82 | 2.03 % | $ 376 M | USA |
 |
Organovo Holdings
ONVO
|
-12.6 M | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
325 K | - | -16.95 % | $ 1.54 M | USA |
 |
Pacific Biosciences of California
PACB
|
-554 M | $ 1.45 | 8.21 % | $ 435 M | USA |
 |
Psychemedics Corporation
PMD
|
-2.92 M | - | -1.84 % | $ 15.3 M | USA |